On April 26th, Novagali announced that the FDA had granted their IND to go ahead with Phase III clinicals for Nova22007 for moderate to severe dry eye.

Nova22007 is a Cyclosporine A ophthalmic product intended to be used to treat patients suffering from moderate-to-severe Dry Eye Syndrome. Nova22007 is a proprietary cationic emulsion enabling an optimal penetration of Cyclosporine A in tissues of the eye surface that benefit from Novasorb® cationic emulsion technology features.

Click here for press release.